Predominant Founder Effect among Recurrent Pathogenic Variants for an X-Linked Disorder

Genes (Basel). 2022 Apr 12;13(4):675. doi: 10.3390/genes13040675.

Abstract

For disorders with X-linked inheritance, variants may be transmitted through multiple generations of carrier females before an affected male is ascertained. Pathogenic RS1 variants exclusively cause X-linked retinoschisis (XLRS). While RS1 is constrained to variation, recurrent variants are frequently observed in unrelated probands. Here, we investigate recurrent pathogenic variants to determine the relative burden of mutational hotspot and founder allele events to this phenomenon. A cohort RS1 variant analysis and standardized classification, including variant enrichment in the XLRS cohort and in RS1 functional domains, were performed on 332 unrelated XLRS probands. A total of 108 unique RS1 variants were identified. A subset of 19 recurrently observed RS1 variants were evaluated in 190 probands by a haplotype analysis, using microsatellite and single nucleotide polymorphisms. Fourteen variants had at least two probands with common variant-specific haplotypes over ~1.95 centimorgans (cM) flanking RS1. Overall, 99/190 of reportedly unrelated probands had 25 distinct shared haplotypes. Examination of this XLRS cohort for common RS1 haplotypes indicates that the founder effect plays a significant role in this disorder, including variants in mutational hotspots. This improves the accuracy of clinical variant classification and may be generalizable to other X-linked disorders.

Trial registration: ClinicalTrials.gov NCT02471287 NCT00378742.

Keywords: ACMG/AMP variant interpretation guideline; RS1; X-linked disorder; X-linked retinoschisis (XLRS); founder effect; haplotype analysis; variant classification.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Eye Proteins / genetics
  • Female
  • Founder Effect
  • Genes, X-Linked*
  • Humans
  • Male
  • Mutation
  • Retinoschisis* / diagnosis
  • Retinoschisis* / genetics
  • Retinoschisis* / pathology

Substances

  • Eye Proteins

Associated data

  • ClinicalTrials.gov/NCT02471287
  • ClinicalTrials.gov/NCT00378742